depression

Towards clinical implementation of pharmacogenomics to improve the treatment of people with depression in BC

In Canada, more than 1 in 10 people will suffer a major form of depression at some point in their lives. There are many effective treatments for depression, including drug therapy. Finding a medication that both works and does not cause severe side effects is often a matter of trial-and-error. This may contribute to the high non-adherence rates and, subsequently, to poorer health outcomes and increased costs. An individual’s genetic makeup is thought to be partly related to whether particular drugs work and whether there are side effects with the drug.

Primary Investigator: 
Award Type: 
Year: 
2020

Virtual Reality for Cognitive Training in Depression: the bWell Cognitive Care Platform

Many patients with depression struggle to return to their full level of functioning in work and other areas of life. These poor functional outcomes in depression may be related to cognitive difficulties, as patients demonstrate problems with memory, attention, and problem solving. We however lack treatments for these difficulties. Cognitive training, consisting of tasks to target cognitive deficits, has been tested but shows inconsistent results in depression.      

Primary Investigator: 
Year: 
2019

Implementing land-based resiliency in First Nations youth: The 'This is Who We Are' Program

Dr. Adrienne Chan’s work is funded through the Canadian Institutes of Health Research (CIHR) Pathways to Health Equity for Aboriginal Peoples Initiative. MSFHR is providing match funding, with additional support provided by the Fraser Health Authority and Vancouver Coastal Health. The goal of the Pathways Initiative is to facilitate research on the design, implementation and scale-up of effective programs and policies that address pressing Aboriginal health issues in four priority areas, including suicide.

Primary Investigator: 
Award Type: 
Year: 
2017

Predicting depressive symptoms during the transition to high school

The transition to high school is a challenging developmental period, during which prevalence rates of depression more than double. In fact, by the end of the first year of high school, 11.5% of adolescents will have experienced a depressive episode in the last year, and many more adolescents will have experienced elevated depressive symptoms that interfere with school performance, social friendships, or physical health.

Primary Investigator: 
Award Type: 
Year: 
2018

Neuromodulation research program for youth addiction and mental health

Each year, approximately 1 in 5 Canadians experiences a mental health or addiction problem. Young people aged 15 to 24 are more likely to experience mental illness and substance use than other age groups.

Depression is one of the most common mental illness, but current treatments are either ineffective or lead to side effects in up to 50% of youth. In youth, medications are often borrowed from adult population not accounting for age-related brain differences. New solutions are needed to address major gaps in treatment of youth mental health.

Primary Investigator: 
Award Type: 
Year: 
2018

Precise prescription of rTMS for treatment resistant depression

Dr. Vila-Rodriguez's research will work towards improving diagnostic accuracy and treatment outcomes in persons suffering treatment-resistant depression (TRD). By incorporating neurophysiological-based biomarkers (NPBs) into clinical practice, treatment response can be more easily predicted, preventing relapse in patients with major depressive disorder.

Primary Investigator: 
Award Type: 
Year: 
2017
Health Category: 

Socio-demographic and behavioural factors: Impact on cardiac patients' access to and outcomes from care

Dr. Mackay’s program of research aims to explore the effects of ethnicity on certain critical junctures in cardiac care: seeking treatment in an Emergency Department when having symptoms of acute coronary syndrome; decision-making regarding revascularization or other treatment for coronary artery disease; outcomes following revascularization procedures (i.e., angioplasty and coronary artery bypass surgery); and discharge from acute care of cardiac patients who have screened positive for depression.

Primary Investigator: 
Award Type: 
Year: 
2014

Socioeconomic status as a predictor of prenatal mental health, use of selective serotonin reuptake inhibitors during pregnancy, and infant outcomes

During pregnancy, approximately 15 per cent of women experience depression requiring medical intervention. Although these conditions are often treated with Serotonin Reuptake Inhibitor (SRI) antidepressants, these drugs are reported to increase the risks of adverse infant outcomes, including preterm birth, small for gestational age (SGA) birth, respiratory distress, and some congenital heart malformations.

Primary Investigator: 
Award Type: 
Year: 
2011
Health Category: 

Serotonergic mechanisms underlying sex differences in stress neuroendocrine function

Depressive disorders are a leading global cause of disability. Although the incidence of depressive disorders is two-fold higher in women compared to men, the neurobiological basis for this disparity is unknown. Depressive disorders are often characterized by elevated blood levels of the glucocorticoid steroid hormone, cortisol. In both humans and rodents, females secrete greater levels of glucocorticoids than males in response to stress, which may at least partially explain the increased rates of affective disorders in women.

Primary Investigator: 
Award Type: 
Year: 
2011
Health Category: 

Alterations in neural circuits mediating executive and decision making functions by chronic psychostimulant exposure

Emotional processes and higher order executive functions are governed in part by interconnected neural networks that link the amygdala (a brain nucleus in the temporal lobes) to the frontal lobes. Drug addicts, particularly those abusing psycho-stimulants such as amphetamine or cocaine, show impaired cognitive function specific to these particular brain circuits.

Primary Investigator: 
Award Type: 
Year: 
2008
Subscribe to RSS - depression